Added by | standudu |
---|---|
Group name | EquipeCTCS |
Item Type | Attachment |
Title | PubMed entry |
URL | http://www.ncbi.nlm.nih.gov/pubmed/34625861 |
Accessed | 2022/07/29 - 14:00:43 |
Date Added | 2022/07/29 - 12:00:43 |
Date Modified | 2022/07/29 - 12:00:43 |
Parent item | Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |